Paclitaxel nanoparticle - InnoUp Farma/University of Navarra
Alternative Names: INP-12Latest Information Update: 12 Jul 2023
At a glance
- Originator InnoUp Farma; University of Navarra
- Developer InnoUp Farma
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 12 Jul 2023 Preclinical trials in Breast cancer in Spain (PO) (InnoUp Farma pipeline, July 2023)